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 Abstract 
 The interest for the sphenopalatine ganglion (SPG) in neurovascular headaches dates back to 1908 
when Sluder presented his work on the role of the SPG in ‘nasal headaches’, which are now part of 
the trigeminal autonomic cephalalgias and cluster headache (ICHD-III-beta). Since then various 
 interventions with blocking or lesional properties have targeted the SPG (transnasal injection of li-
docaine and other agents, alcohol or steroid injections, radiofrequency lesions, or even ganglionec-
tomy); success rates vary, but benefit is usually transient. Here we briefly review some anatomo-
physiological characteristics of the SPG and hypotheses about its pathophysiological role in 
neurovascular headaches before describing recent therapeutic results obtained with electrical stim-
ulation of the SPG. Based on results of a prospective randomized controlled study, SPG stimulation 
appears to be an effective treatment option for patients with chronic cluster headaches; efficacy data 
indicate that acute electrical stimulation of the SPG provides significant attack pain relief and in many 
cases pain freedom compared to sham stimulation. Moreover, in some patients SPG stimulation has 
been associated with a significant and clinically meaningful reduction in cluster headache attack 
frequency; this preventive effect of SPG stimulation warrants further investigation. For migraine at-
tacks, the outcome of a proof-of-concept study using a temporary electrode implanted in the ptery-
gopalatine fossa was less encouraging; however, an ongoing multicenter trial is evaluating the ef-
ficacy of long-term SPG stimulation against sham stimulation for acute and preventive treatment in 
patients with frequent migraine.  © 2015 S. Karger AG, Basel 
 Interest in the sphenopalatine ganglion (SPG) in neurovascular headaches dates back 
to 1908 when Sluder  [1] presented his work on the ‘role of the sphenopalatine (or 
Meckel’s) ganglion in nasal headaches’, which are now part of the trigeminal auto-
nomic cephalalgias and cluster headache (CH) (ICHD-III-beta)  [2] . Since then vari-
ous interventions with blocking or lesional properties have targeted the SPG such as 
transnasal injection of lidocaine and other agents  [3, 4] , alcohol or steroid injections 
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 [5] , radiofrequency lesions  [6–8] , or even ganglionectomy  [9] . Success rates vary, but 
benefit is usually transient  [10] . 
 We will briefly review some anatomophysiological characteristics of the SPG and 
hypotheses about its pathophysiological role in neurovascular headaches before de-
scribing recent therapeutic results obtained with electrical stimulation of the SPG.
 Anatomophysiology of the Sphenopalatine Ganglion 
 The SPG is the largest extracranial parasympathetic ganglion located in the pterygo-
palatine fossa, where it is closely associated with sensory and sympathetic fibers (see 
review by Khan et al.  [11] ). Its parasympathetic fibers originate in the superior salivary 
nucleus (SSN) of the pons and supply extra- and intracerebral arteries, the lacrimal 
gland, nasal mucosa, and conjunctiva. Sympathetic fibers come from the pericarotid 
plexus and pass through the SPG to innervate the lacrimal gland and nasal and pala-
tine mucosa. Only a few fibers from the sphenopalatine branches of the maxillary 
nerve enter the SPG, forming the sensory root. They innervate areas such as the pos-
terior nasopharynx via the lesser palatine nerve. 
 Physiologically, low-frequency electrical stimulations of the SPG (10–20 Hz) in 
animal studies produce dilatation of intra- and extracranial arteries, increased cere-
bral blood flow and plasma protein extravasation in dura mater.
 The trigeminoparasympathetic reflex consists of a brainstem connection between 
trigeminal afferents and parasympathetic efferents of the facial nerve that synapse in 
the SPG. The reflex was broadly demonstrated in animal and human studies, showing 
that trigeminal ganglion stimulation leads to intra- and extracranial vasodilatation, 
increased regional cerebral blood flow  and increased facial temperature, a response 
that is abolished by lesioning the facial nerve. Thus, when the trigeminal-parasympa-
thetic reflex is activated, the postganglionic parasympathetic fibers from the SPG re-
lease neurotransmitters and vasodilators that activate sensory trigeminal fibers caus-
ing further activation of the trigeminal pain pathway, which in turn causes further 
parasympathetic outflow  [12, 13] ( fig. 1 ).
 Pathogenic Role of the Sphenopalatine Ganglion in Neurovascular Headaches 
 There is no doubt that the cranial autonomic symptoms that characterize CH attacks 
are predominantly due to activation of the parasympathetic system, and thus the SPG. 
It is postulated that upon nociceptive activation of nociceptors belonging to the oph-
thalmic nerve during a CH attack, the trigeminoparasympathetic reflex is activated. 
Fibers from the trigeminocervical complex project to the superior salivatory nucleus 
and activate facial parasympathetic efferents. As parasympathetic activation leads 
to vasodilation of meningeal arteries, a vicious circle further increasing trigeminal 
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 activation has been proposed  [14] . This hypothesis is supported by a recent study 
showing that low-frequency stimulation of the SPG is able to induce attacks in CH 
patients  [15] . Interestingly, low-frequency stimulation of the SSN in cats leads to fir-
ing of trigeminovascular neurons in the trigeminocervical complex, which is inhib-
ited by oxygen inhalation, an established treatment for CH attacks  [16] . 
 Cranial autonomic symptoms may also occur during migraine attacks, although 
they are usually less prominent than in CH. As mentioned, SPG activation produces 
meningeal vasodilatation and plasma protein extravasation, both of which may be in-
volved in migraine pathogenesis  [11] . Burstein and Jakubowski  [17] have proposed 
that common migraine triggers, such as stress, may activate brain areas that project 
to the SSN. The SSN would then stimulate the release of vasoactive intestinal peptide, 
nitric oxide, and acetylcholine from meningeal terminals of SPG neurons. The result-
ing dilatation of intracranial blood vessel and local release of inflammatory molecules 
would activate meningeal nociceptors, and thus produce the migraine headache. The 
results of a randomized controlled trial (RCT) showing that during a migraine attack 
intranasal lidocaine 4% is able to relieve the headache in 35.8% of patients  [18] could 
be considered as support for the ‘parasympathetic’ theory of migraine pathogenesis. 
However, there is no proof that lidocaine acts on the headache only via the SPG, and 
not by influencing sensory afferents. All things considered, the experimental evidence 
that the trigeminoparasympathetic circuit is pathogenically relevant is much weaker 
in migraine than in CH.
 Fig. 1. Schematic outline of 
the trigeminoparasympathetic 
circuit. Trigeminovascular 
afferents (dark lines) belonging 
to the visceral part of the 
ophthalmic nerve innervate 
the meninges and relay in the 
spinal trigeminal nucleus, from 
where the SSN can be 
activated via nucleus tractus 
solitarius. The parasympathetic 
fibers (gray dashed lines) 
innervate meningeal vessels, 
lacrimal glands, and nasal 
mucosa via the SPG, producing 
cranial autonomic symptoms 
on the side of the headache. 
The SSN can activate 
trigeminovascular nociceptors 
in the spinal trigeminal 
nucleus and can be activated 
by descending afferents, e.g. 
from the hypothalamus. 
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 The SPG is thought to play a role in other pain syndromes besides headaches like 
trigeminal and sphenopalatine neuralgia, atypical facial pain, muscle pain, vasomotor 
rhinitis, eye disorders, and herpes infection. Clinical trials have shown that SPG 
blockade can be helpful in these pain disorders  [19] .
 Sphenopalatine Ganglion Neurostimulation: Available Data 
 The data showing that blocking or lesioning the SPG may be helpful in neurovascular 
headaches and that low-frequency stimulation of the SPG in animals induces changes 
that may be associated with migraine and CH attacks led to the concept that high-
frequency stimulation might on the contrary have an inhibitory effect that would be 
beneficial for acute treatment  [11] .  
 Cluster Headache 
 It is commonly accepted that subcutaneous injections of the 5-HT1B/D agonist sumat-
riptan are at present the most effective treatment for CH attacks. In the sole available 
RCT  [20] , pain relief and pain freedom at 15 min was obtained in 74 and 46% of patients, 
respectively. Sumatriptan, however, is contraindicated in patients with cardiovascular 
disease, and many CH patients are heavy smokers and thus at risk for cardiovascular 
disease. The next most effective acute therapy after sumatriptan is oxygen inhalation, 
which has a 78% success rate  [21] . Various preventive treatments are available for CH 
such as steroids, verapamil, lithium, topiramate, methysergide, and valproate, but their 
use may be limited by intolerance or contraindications  [22] . Moreover, 10–20% of pa-
tients develop the chronic form of CH without remissions and many of them become 
resistant to preventive drugs. In such patients, invasive neurostimulation methods were 
studied and found useful in 60–70% of the patients. Deep hypothalamic stimulation is 
effective but risky. Occipital nerve stimulation is as effective, but also associated with a 
rather high incidence of adverse effects, e.g. lead migration, infection, and battery deple-
tion (for a review, see Magis and Schoenen  [23] ). Therefore, there is room in CH for 
safer acute treatments and for more effective and better tolerable preventive therapies. 
 In 2010, a proof-of-concept study on the response of CH patients to acute electri-
cal stimulation of the SPG was published by Ansarinia et al.  [24] . In 6 patients in 
whom attacks occurred spontaneously or were induced in the hospital, stimulation of 
the SPG with a removable stimulating electrode introduced in the pterygopalatine 
fossa abolished pain in 11 of 18 attacks (61%) and reduced pain by  ≥ 50% in 3 more 
attacks. Based on these data, Autonomic Technologies Inc. (ATI; Redwood, Calif., 
USA) developed an implantable SPG microstimulator and sponsored a prospective, 
randomized, blinded, multicenter study (Pathway CH-I) to test its efficacy and safety 




 The ATI SPG Neurostimulator is implanted under general anesthesia using a mini-
mally invasive, transoral, gingival buccal technique such that the stimulating elec-
trodes on the integral lead are positioned within the pterygopalatine fossa close to 
the SPG and the body – on the lateral-posterior maxilla medial to the zygoma and 
anchored to the zygomatic process of the maxilla ( fig. 2 ). The position of the SPG 
Neurostimulator is verified with an X-ray immediately after implantation, and, if 
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 Fig. 2. The ATI Neurostimulator Pulsante TM ( a , available in four lengths) is a miniaturized device with 
an integral lead containing six electrodes that is implanted in the pterygopalatine fossa through the 
gums of the upper maxilla.  b Lateral and anteroposterior X-rays showing the neurostimulator body 
anchored to the zygomatic process of the maxilla and the lead with its tip next to the anatomical 
location of the sphenopalatine ganglion. The handheld ATI Remote Controller ( c ) is positioned by 
the patient on the jaw to activate the implanted neurostimulator; it also allows the physician to pro-
gram the stimulation parameters ( d ) (images courtesy of Autonomic Technologies Inc.) .
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in 6 European clinical sites participated in the Pathway CH-I study. After postim-
plantation healing and titration periods, 4 patients had dropped out and 28 with a 
mean weekly attack frequency of 17.4 were randomized 1: 1:1 to effective, subthresh-
old, or sham stimulation during an 8-week or 30-attack experimental period. Pa-
rameters of effective stimuli were adjusted to provoke paresthesias in the root of the 
nose or a treatment during an attack (mean intensity: 1.6 mA; mean frequency: 
120.4 Hz; mean pulse width: 389.7 μs) and subperception stimuli were at 85% of the 
lowest effective amplitude. Patients were instructed to apply the remote controller 
on the face to treat ipsilateral CH attacks that were at least of moderate pain inten-
sity (categorical pain scale: 0 = none; 1 = mild; 2 = moderate; 3 = severe; 4 = very 
severe) and to stimulate for 15 min, whereafter they were allowed to use acute med-
ications if needed. Pain scores were recorded using a custom electronic headache 
diary included in the ATI Remote Controller prior to each use and 15, 30, 60, and 
90 min after the start of stimulation. The primary efficacy endpoint was pain relief, 
i.e. a change from 2, 3, or 4 on the categorical pain scale to 0 or 1 at 15 min after the 
start of stimulation. Secondary endpoints were pain freedom at 15 min, pain relief 
and freedom at 30, 60, and 90 min, as well as disability changes assessed by the 
Headache Impact Test (HIT-6) and quality of life changes assessed with the Short-
Form Health Survey (SF-36v2). Safety was assessed by tabulating all device- or pro-
cedure-related serious adverse events from the implantation procedure to the end 
of the experimental period. 
 Efficacy Data 
 During the course of study, the SPG stimulation decreased attack frequency in a num-
ber of patients so that out of the 28 evaluable patients only 14 treated enough attacks 
to be analyzed for acute response. Pain relief at 15 min was achieved in 67.1% of at-
tacks treated by these 14 patients with full stimulation, compared to 7.4% after sham 
stimulation and 7.3% after subthreshold stimulation. Pain freedom was obtained in 
34.1 and 1.5%, respectively. Among the 14 patients, 9 (64%) were considered acute 
responders since they had pain relief at 15 min in at least 50% of the full stimulation-
treated attacks. Overall, 9 out of the 28 patients in the experimental period (32%) re-
ported pain relief of 50% or more at 15-min stimulation. 
 Twelve out of the randomized 28 patients (43%) were frequency responders with 
an average 88% reduction of weekly attack frequency. In total, 19 patients out of 28 
(68%) experienced an acute response, a frequency response, or both: n = 7 (25%), n = 
10 (36%), and n = 2 (7%), respectively. SPG stimulation resulted in a statistically and 
clinically significant reduction in headache disability.
 On completion of the Pathway CH-I trial, patients had the opportunity to enroll in 
an open long-term follow-up. Among 14 patients who reached 18 months postim-
plantation, SPG stimulation (average duration 8.6 min) was effective in 84% of the 
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2,166 analyzable attacks. Efficacy was highest (93%) in attacks of moderate severity, 
which were also the most frequent attacks treated with SPG stimulation (72%), and 
lowest in very severe attacks (29%).
 Safety Data 
 As other maxillofacial surgeries, implantation of the ATI Neurostimulator induces 
standard perioperative adverse effects like local pain, swelling, hematoma, seroma, 
and sensory disturbances. Among the 32 operated patients in the Pathway CH-I trial, 
there were 5 device- or procedure-related serious adverse events: 3 misplacements 
needing a revision procedure, and 2 postimplantation migrations of the electrode 
needing explantation. Sensory disturbance in the distribution of the maxillary nerve 
occurred in 81% of the patients with loss of sensation being the most common (21 of 
32 events in 19 of 32 patients). Sensory deficit resolved after an average of 97 days 
(range: 31–259), but in 6 patients, though being mild or moderate, it had not resolved 
at the time of the report, and in one patient with an electrode migration who had to 
be explanted because of neuropathic pain, a mild sensory deficit persisted 1 year after 
the procedure. During and after the Pathway CH-I trial, advancements in surgical in-
struments and additional surgical experience have decreased surgical time by 25%, the 
number of adverse events by 23%, and the rate of explants or revisions by 83%. 
 Mechanism of Action 
 As mentioned above, in a double-blind randomized crossover study, low-frequency 
(5 Hz) stimulation applied to the 6 CH patients implanted with the ATI Neurostimu-
lator triggered an attack in 3 of them. These attacks were effectively treated with high-
frequency (120 Hz) stimulation  [15] . 
 The prominent autonomic symptoms associated with CH attacks result from in-
creased cranial parasympathetic outflow that is thought to activate trigeminal affer-
ents via the trigeminovascular system  [12] . High-frequency electrical stimulation of 
the SPG may block the parasympathetic efferents, thereby turning off the efferent arm 
of the trigeminal-autonomic reflex, which is thought to be due to depletion of stored 
neurotransmitter(s). From a pathophysiological perspective, the positive results of the 
Pathway CH-I trial confirm that the cranial parasympathetic system plays a crucial 
role in the occurrence as well as recurrence of CH attacks.
 Electrical stimulation in the region of the SPG also acts on the neighboring sensory fi-
bers of the maxillary nerve, producing paresthesias in the nasopharynx, soft palate, nasal 
cavity, and palatal gingiva. In the Pathway CH-I study, these paresthesias guided the pro-
gramming of stimulation parameters. Whether the activation of sensory fibers of the max-
illary nerve contributes to the therapeutic effect is unlikely, but remains to be explored.
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 The mechanisms of action may be different between the acute and preventive ef-
fects of SPG stimulation, which is suggested by the absence of a correlation between 
the two effects in many Pathway CH-I patients. Assuming that it can be confirmed in 
an adequate RCT, the preventive effect might be associated with modulation of cen-
ters involved in descending pain control, similar to that found in chronic CH patients 
after occipital nerve stimulation  [26] .
 Migraine 
 For the treatment of migraine attacks, analgesics, NSAIDs, and triptans are currently 
available. Triptans are the most effective, although the pain-free rate hardly exceeds 30% 
after 2 h. Triptans may also have unpleasant side effects and they are contraindicated in 
patients with cardiovascular disease. Moreover, the overuse of analgesics and triptans is 
the most prevalent chronifying factor of migraine  [27] . Preventive therapies in migraine 
have at best a 50% responder rate of 50–60%, and the most efficient preventive drugs 
like the anticonvulsants topiramate and valproate are not tolerated by many patients. In 
addition, patients suffering from chronic migraine become notoriously resistant to pre-
ventive therapies  [28] . Therefore, there is room for more efficacious and better tolerated 
treatments. In the last decade, several neuromodulation methods have been explored, 
including electrical stimulation of peripheral nervous structures  [23] . Transcutaneous 
supraorbital nerve stimulation with a new device was found to be superior to placebo in 
an RCT of episodic migraineurs, but the 50% responder rate was just below 40%  [29] . 
 As mentioned above, there is some evidence for interictal autonomic dysfunctions 
in migraine, and cranial autonomic symptoms can accompany the attack  [11] . It re-
mains to be shown, however, whether these autonomic symptoms are epiphenomena 
due to the trigeminovascular activation or if they also contribute to the headache and 
central sensitization, as suggested by some trials  [27] .
 A proof-of-concept study on the potential utility of SPG stimulation in migraine 
was conducted similarly to that performed in CH  [30] . As for CH, the authors im-
planted a removable stimulation needle lead in the pterygopalatine fossa in 11 patients 
with medically refractory migraine: 9 with medication overuse headache and 2 with 
episodic migraine. The interventions were performed in an outpatient procedure 
room. Patients had spontaneous or induced migraine headaches and were, in a cross-
over protocol, either effectively or sham stimulated at the peak of their headache and 
associated migrainous features, i.e. several hours after pain onset. Patients had 1–3 
peaks of headache stimulated for a mean of 3 min with a mean amplitude of 1.2 V, 
mean frequency of 57 Hz, and mean pulse width of 394 μs.
 SPG stimulation produced complete abolition of pain within 3 min in 5 out of 15 
headache peaks treated in 2 patients (33.3%). In 3 of 15 attacks, <50% headache relief 
was achieved. One patient had headache relief with SPG stimulation, but also with 
sham stimulation. No adverse effects occurred during this study.
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 These results paved the way for the ongoing Pathway MIG-I trial, where the effi-
cacy of effective stimulation with the ATI SPG Neurostimulator is being evaluated 
against sham stimulation for acute and preventive treatment in patients with frequent 
migraine. No data are available yet.
 Conclusions 
 There is evidence that the SPG plays a role in the pathophysiology of neurovascular 
headaches. Based on available studies, the evidence looks much more convincing in 
CH than in migraine. In both headache types, however, there is a need for more 
 efficient and better tolerable treatments, particularly in the most severely affected 
 patients. 
 In experimental animals, low-frequency stimulation of the SPG produces vascular 
and meningeal changes that are thought to be associated with migraine and CH. A 
contrario, stimulation at high frequency is thought to inhibit parasympathetic output 
by exhausting transmitter synthesis and release. Based on this rationale, proof-of-
concept studies have been performed with SPG stimulation by removable needle elec-
trodes implanted in the pterygopalatine fossa during CH or migraine attacks, abolish-
ing the pain in 61 and 33% of attacks, respectively.
 The hitherto only sham-controlled RCT of SPG stimulation was performed in 
chronic CH with the implantable ATI Neurostimulator. In 14 out of 28 evaluable pa-
tients, effective SPG stimulation for 15 min produced significant pain relief in 61% of 
attacks, compared to 7% for ineffective stimulation. Incidentally, this study suggested 
that repeated SPG stimulation was also able to decrease attack frequency. Overall, 25% 
of the patients had an acute response, 36% had a frequency response, and 7% experi-
enced both. The Pathway CH-I trial clearly shows that SPG stimulation with the im-
plantable ATI Neurostimulator is able to abort CH attacks. The possible preventive 
effect needs to be verified in a proper RCT. The acute effect must be weighed against 
the adverse effects of the surgical intervention that are comprised of perioperative lo-
cal symptoms and in particular long-lasting sensory disturbances due to injury of 
branches of the maxillary nerve.
 The patients enrolled in the Pathway CH-I trial were severely disabled chronic CH 
patients. These patients became resistant to the available preventive drugs, but their 
attacks usually still responded fully and rapidly (within 5–10 min) to injectable sumat-
riptan and sometimes to oxygen inhalation. Therefore, they are above all in need of a 
better preventive treatment. SPG stimulation was most effective in attacks of moder-
ate severity and thus treated early. In severe attacks, e.g. which awake patients during 
night, SPG stimulation was much less effective than injectable sumatriptan. One ma-
jor advantage of SPG stimulation, however, is that it can be repeated several times over 
a 24-hour period in patients with multiple attacks and can be used by patients with 
cardiovascular contraindications for injectable sumatriptan.
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 Contrary to SPG stimulation, occipital nerve stimulation has a convincing preven-
tive effect in refractory chronic CH patients as it is seldom useful during an attack. 
Therefore, the two neuromodulation methods are not comparable at this stage, and 
could be complementary. Assuming that the preventive effect of SPG stimulation can 
be proven in CH, the effect size and, more importantly, the benefit/adverse effect ratio 
have to be compared with those of occipital nerve stimulation.
 During migraine attacks, the outcome of the proof-of-concept study using a re-
movable electrode implanted in the pterygopalatine fossa was less encouraging than 
in CH attacks since only 1 out of 3 attacks was interrupted. Nonetheless, an RCT of 
the effect of SPG stimulation with the ATI Neurostimulator (Pathway MIG-I) has 
been launched in frequent migraine. Besides a possible action on the attack, most pa-
tients and their treating practitioners would welcome a stimulation-induced reduc-
tion of attack frequency. 
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